Clinical Trial Update: Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of Org 24448 (an ampakine) for cognitive deficits in schizophrenia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Org 24448

Snippet

Sponsor: University of California, Los Angeles | Conditions: Schizophrenia | Phase 2 | Status: WITHDRAWN